For a stock that had been struggling for significance for much of the past year, this dramatic shift was not merely a rally — ...

Over the past four years, private equity (PE) firms that invested in life science assets have faced a difficult reality.

Canaccord analyst William Plovanic raised the firm’s price target on TriSalus Life Sciences (TLSI) to $12 from $11 and keeps a Buy rating on the ...

On December 11, the United States Patent and Trademark Office granted Atai Life Sciences N.V. a new patent for EMP-01, an ...

Texas’s premier life science conference returns to Houston in November, spotlighting breakthrough innovations in therapeutics, medical technology, and digital health. HOUSTON--(BUSINESS WIRE)--Rice ...

The real estate investment trust has been dealing with challenges in the life-sciences market, and its strategy includes ...

The glut of life science office and lab space in San Diego County rose to an all-time high in 2024 and it’s expected to continue growing this year. Although leasing activity has picked up in recent ...